-
1 Reply
-
“Losmapimod is a foundational clinical asset for Fulcrum that has the potential to become the first approved therapy that targets the root cause of FSHD. Fulcrum believes losmapimod has the potential to slow or halt the progressive muscle weakness that characterizes the condition, which would significantly improve patients’ quality of life,”
Such exciting and hopeful news! Thank you for sharing Selcuk!
Log in to reply.